Table 3

Adjusted OR/HR of safety and efficacy outcomes in different treatment groups

Outcomes	Groups	Adjusted OR/HR (95% CI)	P value
sICH	Non-APT	Ref
	SAPT	0.185 (0.012 to 2.859)	0.227
	DAPT	17.44 (0.519 to 586.332)	0.111
	Total APT	0.781 (0.103 to 5.944)	0.811
Successful recanalisation (mTICI 2b/3)	Non-APT	Ref
	SAPT	1.883 (0.503 to 7.044)	0.347
	DAPT	0.531 (0.055 to 5.090)	0.583
	Total APT	1.410 (0.452 to 4.396)	0.554
Complete recanalisation (mTICI 3)	Non-APT	Ref
	SAPT	2.586 (1.002 to 6.674)	0.05
	DAPT	0.396 (0.115 to 1.363)	0.142
	Total APT	1.384 (0.628 to 3.053)	0.42
Primary outcome: mRS score at 90 days	Non-APT	Ref
	SAPT	0.750 (0.0543 to 1.035)	0.080
	DAPT	1.662 (1.048 to 2.638)	0.031
	Total APT	0.976 (0.740 to 1.287)	0.864
mRS 0–1	Non-APT	Ref
	SAPT	1.887 (0.806 to 4.417)	0.143
	DAPT	5.405 (1.614 to 18.102)	0.006
	Total APT	2.605 (1.244 to 5.455)	0.011
mRS 0–2	Non-APT	Ref
	SAPT	1.127 (0.469 to 2.708)	0.790
	DAPT	2.397 (0.690 to 8.330)	0.169
	Total APT	1.418 (0.661 to 3.041)	0.369
mRS 6	Non-APT	Ref
	SAPT	1.159 (0.290 to 4.634)	0.835
	DAPT	0.008 (0.000 to 0.441)	0.019
	Total APT	0.514 (0.147 to 1.797)	0.297

Adjusted for sex, systolic blood pressure, NIHSS, ASPECTS, atrial fibrillation, hypertension, smoking, other aetiology of TOAST classification, MCA M2/3 segment occlusion site, intravenous thrombolysis, tirofiban, heparin use during, puncture to recanalisation, general anaesthesia, mechanical aspiration and intra-arterial thrombolysis and balloon angioplasty.
aICH, asymptomatic intracranial haemorrhage; APT, antiplatelet; ASPECTS, Alberta Stroke Program Early CT Score; DAPT, dual antiplatelet; MCA, middle cerebral artery; mRS, modified Rankin score; mTICI, modified treatment in cerebral infarction; NIHSS, National Institutes of Health Stroke Scale; SAPT, single antiplatelet; sICH, symptomatic intracranial haemorrhage.